# FDA Approves Encelto as First-Ever Therapy for Idiopathic Macular Telangiectasia Type 2

> fda · REPORTED · 2025-03-06

The FDA approved Encelto (revakinagene taroretcel-lwey) in March 2025, making it the first approved therapy for MacTel Type 2. It is an allogeneic encapsulated cell therapy implant that continuously secretes CNTF into the vitreous cavity of the eye.

- Company: Neurotech Pharmaceuticals
- Sector: therapeutics
- Primary source: https://www.cgtlive.com/view/top-fda-gene-cell-therapy-news-2025-year-end-recap

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.